Daniel Falk

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials
    Daniel Falk
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892 9304, USA
    Alcohol Clin Exp Res 34:2022-34. 2010
  2. ncbi request reprint Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry
    Raye Z Litten
    National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group NCIG RZL, MR, DF, JF, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 38:1196-9. 2014
  3. doi request reprint Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs
    Raye Z Litten
    NIAAA s Collaborative Investigator Group NCIG, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 38:27-32. 2014
  4. pmc The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 37:2128-37. 2013

Detail Information

Publications4

  1. doi request reprint Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials
    Daniel Falk
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892 9304, USA
    Alcohol Clin Exp Res 34:2022-34. 2010
    ..As PSNHDD has been used infrequently in previous alcohol clinical trials, we evaluated the utility and validity of the PSNHDD outcome measure in 2 large alcohol clinical trials...
  2. ncbi request reprint Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry
    Raye Z Litten
    National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group NCIG RZL, MR, DF, JF, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 38:1196-9. 2014
    ..This commentary examines the advantages and caveats of government and academia collaborations with pharmaceutical companies. ..
  3. doi request reprint Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs
    Raye Z Litten
    NIAAA s Collaborative Investigator Group NCIG, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 38:27-32. 2014
    ..Addressing these issues will not only help to improve treatment but, as further described, will also open up many new research opportunities for alcohol investigators in the coming decade. ..
  4. pmc The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 37:2128-37. 2013
    ..A significant placebo response occurs in alcohol trials, but it is not well understood. The purpose of this study was to characterize the placebo response across multiple naltrexone and acamprosate studies...